World Health Assembly Events Series Kicks Off Thursday 13/05/2020 Editorial team Health Policy Watch is the media partner for the Geneva Graduate Institute – Global Health Centre series of World Health Assembly events, running Thursday 14 May to Wednesday 27 May. The series of events is built around themes relevant to the 73rd session of the WHA, 18-19 May, the first ever Assembly to bring together the World […] Continue reading -> Malaria in Pregnancy – MMV Makes Renewed Efforts To Protect This High-Risk Group 01/05/2020 Elaine Ruth Fletcher & Grace Ren Reducing new cases of malaria among pregnant women remains one of the key challenges on the road to malaria elimination – a goal that was celebrated last week, on World Malaria Day, 25 April. Although malaria deaths fell by nearly a quarter between 2010 and 2018, pregnant women remain among the groups most at risk […] Continue reading -> Behind The Scenes Of The MMV Story – From Coartem Dispersible’s ‘Opening Act’ To A New Drug For Relapsing Malaria 23/11/2019 Editorial team Over the last 20 years, MMV has worked with over 400 partner organizations in 55 countries; involving tens of thousands of individuals. At a recent anniversary event held in Geneva, some of those key players told their stories – bringing to life the contributions made by so many more people over the past 20 years. […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Eight New Treatments For World’s Most Neglected Diseases: DNDi’s Pécoul Reflects On Milestones At 15 Year Mark 30/10/2019 Elaine Ruth Fletcher The Drugs for Neglected Diseases Initiative (DNDi) celebrates its 15th anniversary this week, as a non-profit drug R&D organization that sought to create an alternative model for developing drug treatments for the most neglected diseases and the world’s poorest populations. Since DNDi’s launch in 2003, the organization has developed eight new treatments, including the first-ever […] Continue reading -> Bringing Health Innovations To Market Is Key In The Global Fight Against HIV/AIDS, Malaria And Tuberculosis 11/10/2019 John Zarocostas Lyon, France – The global health community needs to scale-up collaborations with product development partnerships (PDPs) that could bring life-saving innovations for prevention, diagnosis, and treatment of HIV/AIDS, Malaria and Tuberculosis to market faster, said health experts at a side event ahead of the Global Fund’s Sixth Replenishment Conference. There are some 55 “potentially transformative” […] Continue reading -> Building the Back End of Health Care Finance & Access 24/09/2019 Elaine Ruth Fletcher If Fernando Arnaiz of Roche Pharmaceuticals had his way, the power of Kenyan mobile phone banking might soon be harnessed to health insurance schemes to finance treatment for cancer and other noncommunicable (NCDs) diseases, treatments accessible to only a tiny proportion of people in Africa today. Arnaiz is part of a unique team at Roche […] Continue reading -> The Global Malaria Response: Extending The Reach Of Primary Health Care, Expanding Coverage Towards UHC 12/06/2019 David Branigan Extending the reach of primary health care systems to provide malaria services to those in the most hard-to-reach places has become part and parcel to the global malaria response, and according to experts, is paving the way for the expansion of other essential health services – and moving the world closer towards realising universal health […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Malaria in Pregnancy – MMV Makes Renewed Efforts To Protect This High-Risk Group 01/05/2020 Elaine Ruth Fletcher & Grace Ren Reducing new cases of malaria among pregnant women remains one of the key challenges on the road to malaria elimination – a goal that was celebrated last week, on World Malaria Day, 25 April. Although malaria deaths fell by nearly a quarter between 2010 and 2018, pregnant women remain among the groups most at risk […] Continue reading -> Behind The Scenes Of The MMV Story – From Coartem Dispersible’s ‘Opening Act’ To A New Drug For Relapsing Malaria 23/11/2019 Editorial team Over the last 20 years, MMV has worked with over 400 partner organizations in 55 countries; involving tens of thousands of individuals. At a recent anniversary event held in Geneva, some of those key players told their stories – bringing to life the contributions made by so many more people over the past 20 years. […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Eight New Treatments For World’s Most Neglected Diseases: DNDi’s Pécoul Reflects On Milestones At 15 Year Mark 30/10/2019 Elaine Ruth Fletcher The Drugs for Neglected Diseases Initiative (DNDi) celebrates its 15th anniversary this week, as a non-profit drug R&D organization that sought to create an alternative model for developing drug treatments for the most neglected diseases and the world’s poorest populations. Since DNDi’s launch in 2003, the organization has developed eight new treatments, including the first-ever […] Continue reading -> Bringing Health Innovations To Market Is Key In The Global Fight Against HIV/AIDS, Malaria And Tuberculosis 11/10/2019 John Zarocostas Lyon, France – The global health community needs to scale-up collaborations with product development partnerships (PDPs) that could bring life-saving innovations for prevention, diagnosis, and treatment of HIV/AIDS, Malaria and Tuberculosis to market faster, said health experts at a side event ahead of the Global Fund’s Sixth Replenishment Conference. There are some 55 “potentially transformative” […] Continue reading -> Building the Back End of Health Care Finance & Access 24/09/2019 Elaine Ruth Fletcher If Fernando Arnaiz of Roche Pharmaceuticals had his way, the power of Kenyan mobile phone banking might soon be harnessed to health insurance schemes to finance treatment for cancer and other noncommunicable (NCDs) diseases, treatments accessible to only a tiny proportion of people in Africa today. Arnaiz is part of a unique team at Roche […] Continue reading -> The Global Malaria Response: Extending The Reach Of Primary Health Care, Expanding Coverage Towards UHC 12/06/2019 David Branigan Extending the reach of primary health care systems to provide malaria services to those in the most hard-to-reach places has become part and parcel to the global malaria response, and according to experts, is paving the way for the expansion of other essential health services – and moving the world closer towards realising universal health […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Behind The Scenes Of The MMV Story – From Coartem Dispersible’s ‘Opening Act’ To A New Drug For Relapsing Malaria 23/11/2019 Editorial team Over the last 20 years, MMV has worked with over 400 partner organizations in 55 countries; involving tens of thousands of individuals. At a recent anniversary event held in Geneva, some of those key players told their stories – bringing to life the contributions made by so many more people over the past 20 years. […] Continue reading -> Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Eight New Treatments For World’s Most Neglected Diseases: DNDi’s Pécoul Reflects On Milestones At 15 Year Mark 30/10/2019 Elaine Ruth Fletcher The Drugs for Neglected Diseases Initiative (DNDi) celebrates its 15th anniversary this week, as a non-profit drug R&D organization that sought to create an alternative model for developing drug treatments for the most neglected diseases and the world’s poorest populations. Since DNDi’s launch in 2003, the organization has developed eight new treatments, including the first-ever […] Continue reading -> Bringing Health Innovations To Market Is Key In The Global Fight Against HIV/AIDS, Malaria And Tuberculosis 11/10/2019 John Zarocostas Lyon, France – The global health community needs to scale-up collaborations with product development partnerships (PDPs) that could bring life-saving innovations for prevention, diagnosis, and treatment of HIV/AIDS, Malaria and Tuberculosis to market faster, said health experts at a side event ahead of the Global Fund’s Sixth Replenishment Conference. There are some 55 “potentially transformative” […] Continue reading -> Building the Back End of Health Care Finance & Access 24/09/2019 Elaine Ruth Fletcher If Fernando Arnaiz of Roche Pharmaceuticals had his way, the power of Kenyan mobile phone banking might soon be harnessed to health insurance schemes to finance treatment for cancer and other noncommunicable (NCDs) diseases, treatments accessible to only a tiny proportion of people in Africa today. Arnaiz is part of a unique team at Roche […] Continue reading -> The Global Malaria Response: Extending The Reach Of Primary Health Care, Expanding Coverage Towards UHC 12/06/2019 David Branigan Extending the reach of primary health care systems to provide malaria services to those in the most hard-to-reach places has become part and parcel to the global malaria response, and according to experts, is paving the way for the expansion of other essential health services – and moving the world closer towards realising universal health […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Non-Profit R&D Can Successfully Bring New Treatments For Neglected Diseases To Market 30/10/2019 Grace Ren Berlin, Germany – A “public interest R&D” model can bring effective treatments for neglected diseases to patients at comparatively low cost, through a collaborative, access-oriented development process. The model is outlined in the new report 15 Years of Needs-Driven Innovation for Access, by Drugs for Neglected Disease Initiative (DNDi), released Wednesday. The model etches an […] Continue reading -> Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Eight New Treatments For World’s Most Neglected Diseases: DNDi’s Pécoul Reflects On Milestones At 15 Year Mark 30/10/2019 Elaine Ruth Fletcher The Drugs for Neglected Diseases Initiative (DNDi) celebrates its 15th anniversary this week, as a non-profit drug R&D organization that sought to create an alternative model for developing drug treatments for the most neglected diseases and the world’s poorest populations. Since DNDi’s launch in 2003, the organization has developed eight new treatments, including the first-ever […] Continue reading -> Bringing Health Innovations To Market Is Key In The Global Fight Against HIV/AIDS, Malaria And Tuberculosis 11/10/2019 John Zarocostas Lyon, France – The global health community needs to scale-up collaborations with product development partnerships (PDPs) that could bring life-saving innovations for prevention, diagnosis, and treatment of HIV/AIDS, Malaria and Tuberculosis to market faster, said health experts at a side event ahead of the Global Fund’s Sixth Replenishment Conference. There are some 55 “potentially transformative” […] Continue reading -> Building the Back End of Health Care Finance & Access 24/09/2019 Elaine Ruth Fletcher If Fernando Arnaiz of Roche Pharmaceuticals had his way, the power of Kenyan mobile phone banking might soon be harnessed to health insurance schemes to finance treatment for cancer and other noncommunicable (NCDs) diseases, treatments accessible to only a tiny proportion of people in Africa today. Arnaiz is part of a unique team at Roche […] Continue reading -> The Global Malaria Response: Extending The Reach Of Primary Health Care, Expanding Coverage Towards UHC 12/06/2019 David Branigan Extending the reach of primary health care systems to provide malaria services to those in the most hard-to-reach places has become part and parcel to the global malaria response, and according to experts, is paving the way for the expansion of other essential health services – and moving the world closer towards realising universal health […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Lessons Learned And Challenges Ahead: DNDi Celebrates 15 Years 30/10/2019 Elaine Ruth Fletcher Berlin, Germany – The Drugs for Neglected Diseases Initiative (DNDi) is celebrating its 15th anniversary and in a special event Tuesday night, founders and supporters of the product development partnership (PDP) gathered in Berlin to reflect on lessons learned and challenges that still lie ahead. Here below are excerpts of what they had to say. […] Continue reading -> Eight New Treatments For World’s Most Neglected Diseases: DNDi’s Pécoul Reflects On Milestones At 15 Year Mark 30/10/2019 Elaine Ruth Fletcher The Drugs for Neglected Diseases Initiative (DNDi) celebrates its 15th anniversary this week, as a non-profit drug R&D organization that sought to create an alternative model for developing drug treatments for the most neglected diseases and the world’s poorest populations. Since DNDi’s launch in 2003, the organization has developed eight new treatments, including the first-ever […] Continue reading -> Bringing Health Innovations To Market Is Key In The Global Fight Against HIV/AIDS, Malaria And Tuberculosis 11/10/2019 John Zarocostas Lyon, France – The global health community needs to scale-up collaborations with product development partnerships (PDPs) that could bring life-saving innovations for prevention, diagnosis, and treatment of HIV/AIDS, Malaria and Tuberculosis to market faster, said health experts at a side event ahead of the Global Fund’s Sixth Replenishment Conference. There are some 55 “potentially transformative” […] Continue reading -> Building the Back End of Health Care Finance & Access 24/09/2019 Elaine Ruth Fletcher If Fernando Arnaiz of Roche Pharmaceuticals had his way, the power of Kenyan mobile phone banking might soon be harnessed to health insurance schemes to finance treatment for cancer and other noncommunicable (NCDs) diseases, treatments accessible to only a tiny proportion of people in Africa today. Arnaiz is part of a unique team at Roche […] Continue reading -> The Global Malaria Response: Extending The Reach Of Primary Health Care, Expanding Coverage Towards UHC 12/06/2019 David Branigan Extending the reach of primary health care systems to provide malaria services to those in the most hard-to-reach places has become part and parcel to the global malaria response, and according to experts, is paving the way for the expansion of other essential health services – and moving the world closer towards realising universal health […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Eight New Treatments For World’s Most Neglected Diseases: DNDi’s Pécoul Reflects On Milestones At 15 Year Mark 30/10/2019 Elaine Ruth Fletcher The Drugs for Neglected Diseases Initiative (DNDi) celebrates its 15th anniversary this week, as a non-profit drug R&D organization that sought to create an alternative model for developing drug treatments for the most neglected diseases and the world’s poorest populations. Since DNDi’s launch in 2003, the organization has developed eight new treatments, including the first-ever […] Continue reading -> Bringing Health Innovations To Market Is Key In The Global Fight Against HIV/AIDS, Malaria And Tuberculosis 11/10/2019 John Zarocostas Lyon, France – The global health community needs to scale-up collaborations with product development partnerships (PDPs) that could bring life-saving innovations for prevention, diagnosis, and treatment of HIV/AIDS, Malaria and Tuberculosis to market faster, said health experts at a side event ahead of the Global Fund’s Sixth Replenishment Conference. There are some 55 “potentially transformative” […] Continue reading -> Building the Back End of Health Care Finance & Access 24/09/2019 Elaine Ruth Fletcher If Fernando Arnaiz of Roche Pharmaceuticals had his way, the power of Kenyan mobile phone banking might soon be harnessed to health insurance schemes to finance treatment for cancer and other noncommunicable (NCDs) diseases, treatments accessible to only a tiny proportion of people in Africa today. Arnaiz is part of a unique team at Roche […] Continue reading -> The Global Malaria Response: Extending The Reach Of Primary Health Care, Expanding Coverage Towards UHC 12/06/2019 David Branigan Extending the reach of primary health care systems to provide malaria services to those in the most hard-to-reach places has become part and parcel to the global malaria response, and according to experts, is paving the way for the expansion of other essential health services – and moving the world closer towards realising universal health […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Bringing Health Innovations To Market Is Key In The Global Fight Against HIV/AIDS, Malaria And Tuberculosis 11/10/2019 John Zarocostas Lyon, France – The global health community needs to scale-up collaborations with product development partnerships (PDPs) that could bring life-saving innovations for prevention, diagnosis, and treatment of HIV/AIDS, Malaria and Tuberculosis to market faster, said health experts at a side event ahead of the Global Fund’s Sixth Replenishment Conference. There are some 55 “potentially transformative” […] Continue reading -> Building the Back End of Health Care Finance & Access 24/09/2019 Elaine Ruth Fletcher If Fernando Arnaiz of Roche Pharmaceuticals had his way, the power of Kenyan mobile phone banking might soon be harnessed to health insurance schemes to finance treatment for cancer and other noncommunicable (NCDs) diseases, treatments accessible to only a tiny proportion of people in Africa today. Arnaiz is part of a unique team at Roche […] Continue reading -> The Global Malaria Response: Extending The Reach Of Primary Health Care, Expanding Coverage Towards UHC 12/06/2019 David Branigan Extending the reach of primary health care systems to provide malaria services to those in the most hard-to-reach places has become part and parcel to the global malaria response, and according to experts, is paving the way for the expansion of other essential health services – and moving the world closer towards realising universal health […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Building the Back End of Health Care Finance & Access 24/09/2019 Elaine Ruth Fletcher If Fernando Arnaiz of Roche Pharmaceuticals had his way, the power of Kenyan mobile phone banking might soon be harnessed to health insurance schemes to finance treatment for cancer and other noncommunicable (NCDs) diseases, treatments accessible to only a tiny proportion of people in Africa today. Arnaiz is part of a unique team at Roche […] Continue reading -> The Global Malaria Response: Extending The Reach Of Primary Health Care, Expanding Coverage Towards UHC 12/06/2019 David Branigan Extending the reach of primary health care systems to provide malaria services to those in the most hard-to-reach places has become part and parcel to the global malaria response, and according to experts, is paving the way for the expansion of other essential health services – and moving the world closer towards realising universal health […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Global Malaria Response: Extending The Reach Of Primary Health Care, Expanding Coverage Towards UHC 12/06/2019 David Branigan Extending the reach of primary health care systems to provide malaria services to those in the most hard-to-reach places has become part and parcel to the global malaria response, and according to experts, is paving the way for the expansion of other essential health services – and moving the world closer towards realising universal health […] Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Posts navigation Older posts